Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
Revenue Growth Under Pressure
Trending lower.
Left:
||||
Year-over-year revenue growth rate
Latest
33.13%
Near historical average
Average (39q)
35.67%
Historical baseline
Range
High:445.52%
Low:-80.05%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 33.13% |
| Q2 2025 | 84.09% |
| Q1 2025 | -47.63% |
| Q4 2024 | -24.11% |
| Q3 2024 | 168.39% |
| Q2 2024 | -2.49% |
| Q1 2024 | -30.84% |
| Q4 2023 | 67.58% |
| Q3 2023 | -61.36% |
| Q2 2023 | 35.16% |
| Q1 2023 | 24.60% |
| Q4 2022 | -36.12% |
| Q3 2022 | -34.15% |
| Q2 2022 | -13.06% |
| Q1 2022 | 445.52% |
| Q4 2021 | -56.40% |
| Q3 2021 | 399.32% |
| Q2 2021 | 50.51% |
| Q1 2021 | 76.51% |
| Q4 2020 | -51.46% |
| Q3 2020 | 245.45% |
| Q2 2020 | -40.36% |
| Q1 2020 | -80.05% |
| Q4 2019 | 283.41% |
| Q3 2019 | -13.20% |
| Q2 2019 | 39.66% |
| Q1 2019 | 4.68% |
| Q4 2018 | -35.23% |
| Q3 2018 | -56.44% |
| Q2 2018 | 61.60% |
| Q1 2018 | -34.09% |
| Q4 2017 | 22.89% |
| Q3 2017 | 21.52% |
| Q2 2017 | 0.53% |
| Q1 2017 | -50.00% |
| Q4 2016 | 94.36% |
| Q3 2016 | -22.92% |
| Q2 2016 | -13.65% |
| Q1 2016 | 5.59% |
| Q4 2015 | -33.93% |